Georgia Tech researchers used high-performance mass spectrometry to uncover a highly accurate 16-marker signature that identifies women with ovarian cancer.

NEW YORK (GenomeWeb News) – Waters today reported that its revenues in the first quarter were up 2 percent year over year, driven by a resurgence in instrument sales, particularly mass spectrometers.

NEW YORK (GenomeWeb News) – Waters is offering its Acquity UPLC System with online solid phase extraction technology from Spark Holland under a deal announced today between the firms.

NEW YORK (GenomeWeb News) – Waters and the UK's The Food and Environment Research Agency today announced they are establishing a laboratory-based training facility to improve food safety detection.

The companies will co-market mass spectrometry tools with characterization software.

According to President and CEO Douglas Berthiaume, LC and mass spec instrument sales both grew at rates of over 20 percent as the company saw "continued rapid uptake" of its Acuity H-Class UPLC and Xevo mass spectrometry systems.

New 2010 releases like Waters' Xevo TQ-S triple quadrupole machine and AB Sciex's TripleTOF 5600 helped spur strong revenue growth, said company officials during Q4 earning calls this week.

With executives from Agilent, Thermo Fisher, Waters, and Danaher presenting this week at the JP Morgan Healthcare Conference, UPLC as well as triple quadrupole and qual-quan mass spec proved primary areas of discussion.

The release of a long-awaited protein biomarker test, increased adoption of a major instrument platform, and a pair of proteome mapping milestones marked a year in which several much-anticipated advances in proteomics arrived.


The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.